and Human Services (HHS)
EXPIRED
Department of Health and Human Services
Participating Organizations
National Institutes of Health (NIH), (http://www.nih.gov/)
Components of Participating Organizations
National Institute on Drug Abuse (NIDA), (http://www.nida.nih.gov/)
Title: Minority Institutions' Drug Abuse Research Development Program (MIDARP)
Announcement Type
This is a reissue of PAR-02-016, which was previously released October 22, 2001.
Update: The following update relating to this announcement has been issued:
Program Announcement (PA) Number: PAR-05-069
Catalog of Federal Domestic Assistance Number(s)
93.279
Key Dates - (Old Dates)
Release Date: March 15, 2005
Letters of Intent Receipt Date(s): July 15, 2005; March 13 and July 17, 2006; March 12 and July 16, 2007; and March 12, 2008. AIDS Letter of Intent Receipt Dates: December 2, 2005; August 2, 2006; December 1, 2006; August 1, 2007; December 3, 2007; August 1, 2008.
Application Receipt Dates(s): August 16, 2005; April 12 and August 16, 2006; April 12 and August 16, 2007; April 12, 2008 AIDS receipt date(s): January 2, 2006; September 1, 2006; January 2, 2007; September 3, 2007; January 2, 2008; September 1, 2008. http://grants.nih.gov/grants/funding/submissionschedule.htm
Peer Review Date(s): December of 2005, August and December of 2006, August and December of 2007, August of 2008. AIDS Peer Review Dates: March 2006, December 2006, March 2007, December 2007, March 2008, December 2008
Council Review Date(s): May 2006, February 2007, May 2007, February 2008, May 2008, February 2009. http://grants.nih.gov/grants/funding/submissionschedule.htm
Earliest Anticipated Start Date: May 2006, February 2007, May 2007, February 2008,May 2008, February 2009. http://grants.nih.gov/grants/funding/submissionschedule.htm
Additional Information To Be Available Date (Url Activation Date): Not Applicable
Expiration Date: September 2, 2008
Key Dates - (New Dates)
Release Date: March 15, 2005
Letters of Intent Receipt Date(s): June 13, 2007; October 14, 2007, and June 15, 2008.
Application Receipt Date(s): July 13, 2007, November 14, 2007, and July 15, 2008.
AIDS Letters of Intent Receipt Date(s): August 7, 2007, December 7, 2007, August 7, 2008
AIDS Receipt Dates: September 7, 2007, January 7, 2008, and September 7, 2008. http://grants.nih.gov/grants/funding/submissionschedule.htm
Peer Review Date(s): November 2007, March 2008, and November
Council Review Date(s January 2008, May 2008, and January 2009. http://grants.nih.gov/grants/funding/submissionschedule.htm
Earliest Anticipated Start Date: April 2008, July 2008, April 2008. http://grants.nih.gov/grants/funding/submissionschedule.htm
Additional Information To Be Available Date (Url Activation Date): Not Applicable
Expiration Date: September 8, 2008
Due Dates for E.O. 12372
Not Applicable
Additional Overview Content
Executive Summary
The National Institute on Drug Abuse, NIH, is providing support to increase research capacity of minority institutions to conduct research in drug abuse and addiction. Grants will be provided to foster research career development of racial/ethnic minority faculty, students and staff who are underrepresented in drug abuse research, and to enhance research infrastructure at minority institutions.
Part II Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
Section II. Award Information
1. Mechanism(s) of Support
2. Funds Available
Section III. Eligibility Information
1. Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2.Cost Sharing or Matching
3. Other - Special Eligibility Criteria
Section IV. Application and Submission Information
1. Address to Request Application Information
2. Content and Form of Application Submission
3. Submission Dates and Times
A. Receipt and Review and Anticipated Start Dates
1. Letter of Intent
B. Sending an Application to the NIH
C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements
Section V. Application Review Information
1. Criteria
2. Review and Selection Process
A. Additional Review Criteria
B. Additional Review Considerations
C. Sharing Research Data
D. Sharing Research Resources
3. Anticipated Announcement and Award Dates
Section VI. Award Administration Information
1. Award Notices
2. Administrative and National Policy Requirements
A. Cooperative Agreement Terms and Conditions of Award
1. Principal Investigator Rights and Responsibilities
2. NIH Responsibilities
3. Collaborative Responsibilities
4. Arbitration Process
3. Reporting
Section VII. Agency Contact(s)
1. Scientific/Research Contact(s)
2. Peer Review Contact(s)
3. Financial/ Grants Management Contact(s)
Section VIII. Other Information - Required Federal Citations
Part II - Full Text of Announcement1. Research Objectives
The purpose of this program is to increase the capacity of minority institutions to conduct research in drug abuse and addiction. Grants will be provided to foster the research career development of racial/ethnic minority faculty, students and staff who are underrepresented in drug abuse research and to conduct research in the drug abuse and addiction research area. All capacity development and research activities must address scientific areas related to the mission and priorities of the National Institute on Drug Abuse.
Program Objectives
Participation of minority institutions and individuals in sponsored biomedical and behavioral research is low. Reasons for this under-representation in research include the following: (1) the primary, historic mission of many minority institutions has been to provide excellent teaching in order to prepare its students for work and/or advanced studies at other institutions; (2) community service has been an important, time-consuming expectation of faculty and staff members; (3) many minority-serving institutions have not had graduate research programs; and (4) support for research (e.g., facilities, equipment, release time, library resources, personnel) has been either unavailable or inadequate.
Minority institutions, however, are redefining and expanding their mission to include a strong emphasis on research and have made strides in recent years to broaden and strengthen their research infrastructure and endeavors. In addition, minority institutions have increased their interest and involvement in drug prevention and treatment programs and are particularly poised to expand these endeavors into the research arena. For example, many are engaged in various drug and HIV/AIDS education, prevention, and training activities; some have current but limited drug abuse research; some have strong ties to community-based organizations, agencies, and schools that are addressing drug abuse problems; and many have indicated interest in developing competency in drug abuse research. This program is intended to provide support to institutions that demonstrate a commitment to developing a supportive environment for fostering research and research careers in drug abuse and addiction.
Thus, the overall goal of the MIDARP is to develop the capacity of the applicant institution to support drug abuse research through the following objectives: (1) provide under-represented minority faculty with drug abuse research knowledge and skill development through the conduct of research projects and other professional development activities (2) encourage under-represented minority students to pursue drug abuse research careers by providing them with educational enrichment and research experiences ; and (3) strengthen the underlying institutional infrastructure needed to support drug abuse research.
Research in any area of drug abuse research supported by NIDA is permissible. NIDA is interested in biomedical, clinical, and behavioral research and supports research on drug abuse in the following broad areas: epidemiology, etiology, prevention, treatment and services, basic research, and medications development. Research areas of particular interest are on HIV/AIDS as it relates to drug use and abuse and understanding disparities in health related to drug abuse and addiction experienced by racial/ethnic minority populations. Some areas of research such as studies that focus primarily on alcohol use may not be appropriate for primary assignment to NIDA. Applicants are encouraged to consult with NIDA staff before submitting an application to ensure that the chosen area of research focus is appropriate to NIDA's mission.
Each MIDARP application must have a thematic research focus around which all research and training activities are directed. That is, there must be a common research issue or question (e.g., prevention with young adults, what increases adherence to treatment protocols in African Americans) that unites proposed institutional infrastructure development, faculty and student research development activities, and research projects.
Each applicant must provide (1) a description of the institution's current drug abuse research capacity, (2) a faculty development plan, (3) a student recruitment and development plan, (4) research projects, (5) an institutional research infrastructure development plan, (6) justification for the choice of the proposed Program Director (Principal Investigator), (7) the inclusion and description of an external advisory board, (8) a letter of institutional commitment signed by a Dean or other institutional official with authority to commit institutional resources, and (9) an impact assessment statement.
1. Current Drug Abuse Research Capacity
The strategy for building research capacity should be based upon assessments of the applicant institution's current level of drug abuse research, its capacity for research in areas other than drug abuse, environmental factors, levels of commitment, and availability of support. Assessments should examine not only needs but also strengths and resources which currently exist and upon which further capacity could be built. Other resources to consider include sponsored research office support, curricula offerings, faculty release time, students' interest, and collaborative arrangements.
2. Faculty Development Plan
The plan should detail the experiences and support intended for faculty members who are selected as project directors, i.e., leaders of primary or pilot projects, and how providing these experiences will increase their ability to conduct drug abuse related research. Much of the faculty development is expected to come from active involvement in the primary and/or pilot research projects (see section below) supported by the program and through other career development activities such as workshops and training. A recruitment plan specifying the criteria that will be used to select faculty members to serve as research project directors should be included. In addition, brief individualized plans must be submitted for these faculty members/project directors. Plans should include support for grant writing and development, research administration, effectively mentoring students in drug abuse and research, research design, data analysis, scientific writing and publishing. In addition, institutional support of the faculty project directors should be addressed including release time and committee obligations.
Faculty members who are currently conducting drug abuse research sponsored by other sources (e.g., federal, state, private sector) may be designated as associate project directors. They may request funds to support minority undergraduate or graduate students to serve as Research Assistants on their already funded projects. MIDARP funds may not be used to replace any research assistant positions supported by other federal or non-federal awards, and strong explanation of the benefits to be gained by the proposed research assistants and the research itself must be provided.
3. Student Recruitment and Development Plan
The student development plan should describe the educational and training experiences that will be provided to stimulate student interest in drug abuse and addiction research and to prepare students to pursue careers in drug abuse and addiction. A recruitment plan for students who will serve as student research assistants on research projects supported by the program should be detailed. It is expected that students selected for participation in research activities will be provided with other research development opportunities such as participation in relevant conferences and mentoring in scientific writing. Activities may be proposed to increase knowledge about drug abuse and career opportunities in drug abuse research for all students, e.g., classes and seminars.
4. Research Projects
The program will provide support for primary and pilot research projects. Primary research projects refer to research studies that have well-specified specific aims, hypotheses, methods, and data analysis plans; however, they are not expected to provide the level of detailed description characteristic of R01 applications. Primary research projects should not exceed 10 pages in length each (see Application Procedures). Pilot projects refer to research studies that seek to establish the feasibility or merit of a particular area of inquiry. They are expected to yield findings that address, for example, confirmation of the significance of the research, feasibility of the methods, and refinement/delineation of hypotheses. Convincing justification of the potential significance of the research to the field should be made even though methods and hypotheses may be in their early formative stages. Pilot projects should not exceed five pages in length each (see Application Procedures). The applicants are expected to clearly indicate which of the proposed research projects are primary and which are pilot.
At least two research projects must be proposed. No more than five research projects can be included. These projects must relate to the research theme or focus area and the institutional infrastructure support that the applicant intends to develop. A participating faculty member may serve as project director only on one research project.
Project Directors are responsible for the administration and implementation of their projects, with the guidance and support of the MIDARP Program Director and the advisory board. In addition to costs associated with conducting the studies, project directors may request support for minority undergraduate and graduate students underrepresented in the biomedical and behavioral sciences to serve as research assistants.
The MIDARP must have at least one primary research project active in all years of support. This requirement may be met either by a single project for the full duration of the award or several projects running sequentially, as long as at least one primary project is active each year. The expectation is that this support in concert with the institutional infrastructure enhancement and faculty development plans will eventually enable the individual project directors to become competitive in sponsored research programs. Securing other support for research projects under the MIDARP umbrella such as from the university, foundations or other NIDA mechanisms is encouraged.
5. Institutional Research Infrastructure Development Plan
The application must describe the support the institution needs in order to meet the drug abuse research infrastructure capacity goals proposed including the resources and facilities the institution needs to implement the proposed research development activities and to conduct the planned research. The plan should address, for example, research equipment, laboratory space, administrative support, collaborative arrangements, and data management and analysis support. A strategy for establishing and evaluating courses, curricula and seminars in areas relevant to research on drug abuse and addiction should also be included as well as plans, if needed, for the enhancement of business and research administration capacity (e.g., IACUC, IRB, grants administration).
6. MIDARP Program Director
Each MIDARP application must have a designated Principal Investigator/Program Director who will be responsible for the scientific and technical direction of the MIDARP. He/She should be a scientist with appropriate training and experience and institutional authority and support to provide effective leadership and guidance to the program and support to project director(s). He/she will be responsible for: (1) recruiting faculty to participate in the MIDARP research development activities; (2) assisting faculty in obtaining appropriate consultation and research mentoring during the grant period; (3) developing the institutional infrastructure required to implement drug abuse research; (4) providing needed fiscal and other project support; (5) recruiting students and providing them with drug abuse research career support and experiences, (6) providing scientific guidance in the research focus area; and (7) providing the overall administration of the grant.
The application should describe the qualifications of the proposed MIDARP Program Director and the resources and supports (e.g., release time, administrative support) the institution will provide him/her to facilitate his/her ability to effectively perform the functions of the MIDARP.
7. External Advisory Board
Plans should include details on establishing an Advisory Board to help guide the MIDARP including the research development and mentoring activities especially in the support of the research projects. Ideally such a panel would consist of three to five external individuals with expertise in the drug abuse research focus area of the MIDARP and in the development of research capacity development programs. Applications should contain a biographical sketch and a letter of commitment from each proposed member to serve on the advisory panel.
8. Letter of Institutional Commitment
The application should include a signed letter from an institutional official with authority to commit the institution to the establishment of the MIDARP. It should detail the resources the institution is willing to provide including office and laboratory space, computer and internet access, library resources, and guarantees of protected time for faculty and students to perform the research and training activities described in the application. The letter should also describe the institution's level of confidence that the MIDARP, under the guidance of the proposed Program Director, will be successful in achieving its goals.
9. Impact assessment
The application should discuss the probable success of the proposed plan by describing the realistic changes that are likely to occur in institutional policies, procedures, resources, and programs germane to the proposed program for drug abuse research and faculty and student development. Applicants are expected to identify areas where development or change is desirable but may be difficult or not possible to address within the scope of the support provided under this program.
Discuss, for example, how the proposed plan will change the institution's ability to develop a drug abuse research focus and agenda; seek and support drug abuse research; prepare its students and faculty for drug abuse research careers and for participation in sponsored research, in general; provide sufficient time and incentives for faculty to engage in drug abuse research; develop collaborations with established searchers/research institutions or drug abuse facilities; and expand library and resource materials.
A plan for conducting an annual impact assessment of the MIDARP is required. This assessment should document the actual impact of the program addressing factors described above and other qualitative and quantitative measures.
10. Progress Report for MIDARP Renewals (Competing Continuations) and Former MIDARP Grantees
MIDARP awards may be renewed through the competing renewal process. The applicant, however, must demonstrate a need for continued development of drug abuse research capacity at his/her institution.
A progress report must be included in competing continuation applications and new applications from institutions that have previously (within the last 5 years) received MIDARP funding. The progress report should describe the advances in drug abuse research capacity development that were achieved as a result of the MIDARP award using the originally proposed impact assessment criteria. Institutional, student, and faculty progress and accomplishments should be fully described in both qualitative and quantitative measures. In addition, report on results of primary research projects and what pilot research projects have accomplished. Examples of progress may include increased faculty publications on drug abuse related topics, increased applications submitted to funding sources, success in obtaining funding, faculty service as peer reviewers, evidence of growth in research skills, creation of new courses or seminars, participation of high quality underrepresented minority faculty and students in MIDARP activities, students pursuing graduate studies in research careers, and patents. A description of the accomplishments of each faculty and student supported by the MIDARP should be included. Faculty and students supported and mentored should be identified by race/ethnicity and gender.
See Section VIII, Other Information - Required Federal Citations, for policies related to this announcement.
Section II. Award Information1. Mechanism(s) of Support
This funding opportunity will use the R24 award mechanism(s). As an applicant, you will be solely responsible for planning, directing, and executing the proposed project. An application may request three to five years of support. MIDARP awards are renewable.
This funding opportunity uses the just-in-time budget concepts. It also uses the non-modular budget format described in the PHS 398 application instructions (see http://grants.nih.gov/grants/funding/phs398/phs398.html). A detailed categorical budget for the "Initial Budget Period" and the "Entire Proposed Period of Support" is to be submitted with the application.
2. Funds Available
The amount of funding to be awarded and the number of awards will depend on the number and scientific merit of the proposals received. R24 awards have a budget of up to $350,000 per year in direct costs for a period of three to five years. The earliest possible start date for applications submitted in response to this program announcement is February 2006. Facilities and administrative costs requested by consortium participants are not included in the direct cost limitation, see http://grants.nih.gov/grants/guide/notice-files/NOT-OD-05-004.html
Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although the financial plans of the IC(s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications.
Section III. Eligibility Information1. Eligible Applicants
1.A. Eligible Institutions
Eligibility Requirements
Institutions applying for this award must demonstrate eligibility through (a) minority designation or (b) minority status and research capacity development need.
Applications may be submitted by an organization, university or college that meets one of the following criteria regarding minority classification:
(a) A public or private nonprofit university, four-year college, or other institution offering undergraduate or graduate degrees with a traditionally high (more than 50 percent) minority (Black, Hispanic, Native American or Alaskan Native, Asian or Pacific Islander) student enrollment. This category of minority designated institutions comprises Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions (HSIs), and Tribal Colleges. An Indian tribe, which in conjunction with one or more institutions of higher learning, offers undergraduate and graduate degrees in disciplines relevant to drug abuse, which has a recognized governing body, and which performs substantial governmental functions, or an Alaska Regional Corporation (ARC) as defined in the Alaska Native Claims Settlement Act (43 U.S.C. 1601 et seq.) is eligible.
(b) A college or university with an under-represented minority student enrollment of at least 25% in each of the previous five years. In addition, these minority status applicants must demonstrate commitment to under-represented minority research development goals through (a) evidence of efforts to recruit faculty and students who are members of minorities nationally underrepresented in behavioral and biomedical research, and (b) demonstration of efforts to provide research support and resources to underrepresented minority faculty and students.
Applicant institutions meeting the minority status requirement under category (2) must also demonstrate that they have a need for research capacity development in drug abuse and addiction. They cannot have received over $500,000 in direct costs from NIH per year in each of the previous five years for research or training in drug abuse and addiction. NIH awards specific to minority institutions including research capacity development awards, as well as support for current MIDARP grantees, are excluded in calculating this total. Excluding the Principal Investigator/Program Director, faculty participating as Project Directors in the proposed MIDARP cannot have been the Principal Investigator on an NIH award in the last five years.
Applications must indicate which of the above two eligibility conditions applies to the institution and provide documentation in support of the eligibility claim. (See APPLICATION PROCEDURES, below.)
Foreign institutions are not eligible to apply.
1.B. Eligible Individuals
Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs.
2. Cost Sharing or Matching
Cost sharing is not required.
The most current Grants Policy Statement can be found at: http://grants.nih.gov/grants/policy/nihgps_2003/nihgps_Part2.htm#matching_or_cost_sharing.
3. Other-Special Eligibility Criteria
There are no other special eligibility criteria. Eligible institutions may submit no more than one application per institution.
1. Address to Request Application Information
The PHS 398 application instructions are available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. Applicants must use the currently approved version of the PHS 398. For further assistance contact GrantsInfo, Telephone (301) 710-0267, Email: [email protected].
Telecommunications for the hearing impaired: TTY 301-451-5936.
2. Content and Form of Application Submission
Applications must be prepared using the most current PHS 398 research grant application instructions and forms. Applications must have a D&B Data Universal Numbering System (DUNS) number as the universal identifier when applying for Federal grants or cooperative agreements. The D&B number can be obtained by calling (866) 705-5711 or through the web site at http://www.dnb.com/us/. The D&B number should be entered on line 11 of the face page of the PHS 398 form.
The title and number of this funding opportunity must be typed on line 2 of the face page of the application form and the YES box must be checked.
Organize the application according to PHS form 398 instructions, except as noted for the following sections and page limits.
1. Revised applications should include an introductory section that presents the applicant's response to the previous critique (3 pages maximum).
2. Overview describing your eligibility for the program (1 page maximum)
3. Research theme/focus and goals of your proposed program; describe how each goal and program component relates to the research theme/focus (3 pages maximum)
4. Current research capacity (5 pages maximum)
5. Research capacity development plan (19 pages maximum excluding research projects) to include:
a. Faculty development plan
b. Student recruitment and development plan
c. Research projectsi. primary research projects. Use format outlined in the PHS form 398, sections a d, 10 pages maximum for each project.
ii. pilot research projects. Use the format outlined in the PHS form 398, sections a d, 5 pages maximum for each projectd. Institutional infrastructure support and resource development plan
6. Impact assessment plan (3 pages maximum)
7. Provide a budget for the overall MIDARP application and for each research project separately.
8. Competing renewal applications should include a section describing the progress that was made in achieving the goals of the previous grant (10 pages maximum). Reprints resulting from previous support may be placed in an appendix.
9. Be sure to complete all other required sections of the PHS form 398 for each of the research projects (e.g., human subjects) and for the proposed program as a whole. New applications should not exceed 30 pages (eligibility page does not count towards this number) excluding the research projects. Applications exceeding the page limits will be returned without review.
3. Submission Dates and Times
Applications must be received by the Center for Scientific Review on or before the receipt date described below (Section IV.3.A). Submission times N/A.
3.A. Receipt, Review and Anticipated Start Dates
Peer Review Date(s): December of 2005, August and December of 2006, August and December of 2007, August of 2008. AIDS Peer Review Dates: March 2006, December 2006, March 2007, December 2007, March 2008, December 2008.; http://grants.nih.gov/grants/funding/submissionschedule.htm
Council Review Date(s): May 2006, February 2007, May 2007, February 2008, May 2008, February 2009. http://grants.nih.gov/grants/funding/submissionschedule.htm
Earliest Anticipated Start Date: May 2006, February 2007, May 2007, February 2008,May 2008, February 2009. http://grants.nih.gov/grants/funding/submissionschedule.htm
3.A.1. Letter of Intent
Prospective applicants are asked to submit a letter of intent that includes the following information:
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
The letter of intent is to be sent by the date listed at the beginning of this document.
The letter of intent should be sent to:
MIDARP
Director
Office of Extramural Affairs
National Institute on Drug Abuse/NIH/DHHS
6101 Executive Boulevard, Suite 220, MSC 8401
Bethesda, MD 20892-8401
Rockville, MD 20852 (for express/courier service)
Telephone: (301) 443-2755
FAX: (301) 443-0538
Email: [email protected]
3.B. Sending an Application to the NIH
Applications must be prepared using the PHS 398 research grant application instructions and forms as described above. Submit a signed, typewritten original of the application, including the checklist, and three signed photocopies, along with appendix, if included, in one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710 (U.S. Postal Service Express or regular mail)
Bethesda, MD 20817 (for express/courier service; non-USPS service)
At the time of submission, two additional copies of the application and all copies of the appendix material must be sent to:
MIDARP
Director
Office of Extramural Affairs
National Institute on Drug Abuse/NIH/DHHS
6101 Executive Boulevard, Suite 220, MSC 8401
Bethesda, MD 20892-8401
Rockville, MD 20852 (for express/courier service)
3.C. Application Processing
Applications must be received on or before the application receipt date(s) described above (Section IV.3.A.). If an application is received after that date, it will be returned to the applicant without review. Upon receipt, applications will be evaluated for completeness by CSR and responsiveness by the NIDA.
The NIH will not accept any application in response to this funding opportunity that is essentially the same as one currently pending initial review unless the applicant withdraws the pending application. The NIH will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of a substantial revision of an application already reviewed, but such application must include an Introduction addressing the previous critique.
Although there is no immediate acknowledgement of the receipt of an application, applicants are generally notified of the review and funding assignment within eight (8) weeks.
4. Intergovernmental Review
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The Grants Policy Statement can be found at http://grants.nih.gov/grants/policy/policy.htm (see also Section VI.3. Reporting).
Allowable Costs
Up to $350,000 in direct costs per year may be requested for a period ranging from three to five years. Funds may be used for activities needed to implement the MIDARP including but not limited to such expenses as salaries and benefits of MIDARP faculty, students and staff at levels commensurate with percent effort expended on MIDARP related administration, research and training activities; time devoted to developing, teaching or participating in courses and/or seminars in drug abuse and addiction; research project costs; travel by faculty and students to scientific meetings; consultant expenses; and advisory board costs. Equipment, administrative personnel, enhancement of IRB/IACUC expertise and similar needs may be funded, as congruent with the assessment of needs and development plans.
Applicants should submit an overall budget for the MIDARP as well as separate budgets for each research project. The total combined direct costs should not exceed $350,000 per year.
6. Other Submission Requirements
Plan for Sharing Research Data
The precise content of the data-sharing plan will vary, depending on the data being collected and how the investigator is planning to share the data. Applicants who are planning to share data may wish to describe briefly the expected schedule for data sharing, the format of the final dataset, the documentation to be provided, whether or not any analytic tools also will be provided, whether or not a data-sharing agreement will be required and, if so, a brief description of such an agreement (including the criteria for deciding who can receive the data and whether or not any conditions will be placed on their use), and the mode of data sharing (e.g., under their own auspices by mailing a disk or posting data on their institutional or personal website, through a data archive or enclave). Investigators choosing to share under their own auspices may wish to enter into a data-sharing agreement. References to data sharing may also be appropriate in other sections of the application.
All applicants must include a plan for sharing research data in their application. The data sharing policy is available at http://grants.nih.gov/grants/policy/data_sharing. All investigators responding to this funding opportunity should include a description of how final research data will be shared, or explain why data sharing is not possible.
The reasonableness of the data sharing plan or the rationale for not sharing research data will be assessed by the reviewers. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score.
Sharing Research Resources
NIH policy requires that grant awardee recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps_2003/index.htm and http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part7.htm#_Toc54600131). Investigators responding to this funding opportunity should include a plan for sharing research resources addressing how unique research resources will be shared or explain why sharing is not possible.
The adequacy of the resources sharing plan and any related data sharing plans will be considered by Program staff of the funding organization when making recommendations about funding applications. The effectiveness of the resource sharing will be evaluated as part of the administrative review of each non-competing Grant Progress Report (PHS 2590, http://grants.nih.gov/grants/funding/2590/2590.htm). See Section VI.3. Reporting.
Section V. Application Review Information1. Criteria
Only the review criteria described below will be considered in the review process.
2. Review and Selection Process
Applications submitted for this funding opportunity will be assigned to NIDA on the basis of established PHS referral guidelines.
Appropriate scientific review groups convened by NIDA in accordance with the standard NIH peer review procedures (http://www.csr.nih.gov/refrev.htm) will evaluate applications for scientific and technical merit.
As part of the initial merit review, all applications will:
The following will be considered in making funding decisions:
Review Criteria
Applications to establish or continue MIDARP programs come from institutions that vary widely in their level of research readiness. Although the following common review criteria will be used, each review will assess the reasonableness of the particular applicant's research development goals and plans based on the applicant's unique resources, needs, capabilities, and expected accomplishments and outcomes. For competing continuation applications, progress in meeting stated goals and objectives will be evaluated.
1. Current Drug Abuse Research Capacity:
Evaluate the described availability of resources or lack thereof, scientific environment and its linkages to the research capacity development plan of the institution to support biomedical and/or behavioral research in general and drug abuse research in particular, considering such elements as:
a. Current faculty involvement and interest in drug abuse related research including current/recent research and participation in drug abuse related professional development activities.
b. Student interest and involvement in drug abuse related research.
c. Current curriculum offerings including courses and seminars in or related to drug abuse research particularly as they relate to the research focus of the proposed MIDARP.
d. Proposed Program Director/Principal Investigator involvement in research and other activities related to drug abuse.
e. Other factors related to the appropriateness of the environment, such as physical plant, instrumentation, financial support, collaborative relationships and opportunities to participate in and discuss scientific research.
f. Degree to which the assessment has taken into account strengths of the institution.
Note: Because the MIDARP is designed to strengthen research capacity, the current capacity assessment, which may be low or high, serves to set the baseline for the research capacity development plan.
2. Faculty/staff development plan in drug abuse research careers.
Evaluate the extent to which the proposed program will provide an appropriate environment for participating faculty and staff to pursue drug abuse research careers; the appropriateness and feasibility of faculty goals relevant to drug abuse research; availability of career development assistance provided to faculty in areas such as scientific writing and publication, research design and analyses, seminars on drug abuse topics; participation in meetings and conferences; mentoring; and research opportunities and support. Are the plans consistent with the current research capacity assessment?
3. Student recruitment and development plans.
Plans should include a description of the pool of available and interested students; the extent to which the proposed program will stimulate drug abuse relevant research/research career interest in students and provide them research experiences; the appropriateness and feasibility of student goals relevant to drug abuse research and careers; career development assistance provided to students in areas such as scientific writing and publication; participation in meetings and conferences; mentoring; research experiences; and preparation for graduate study. Are the plans consistent with the current research capacity assessment?
4. Primary Research Projects
Primary research projects refer to research studies that have well-specified specific aims, background, methods, hypotheses and data analyses plans (but without the detailed description expected in an R01 application). The review committee will evaluate these projects to determine the overall thoroughness of the research plan given the resources and environment and the likelihood that the research as developed will make a worthwhile contribution to the proposed research capacity of the institution.
(a) Value of the study to the field and to the MIDARP's research focus importance of the specific aims or hypotheses/research questions.
(b) Approach of the study: the adequacy and appropriateness of the conceptual framework, design, methods, and analyses; the extent to which the applicant addresses potential and limitations of the research.
(c) Capability of the project director to carry out the work proposed.
(d) Adequacy of institutional resources and support to be made available including sufficient release time, if needed.
Pilot Research Projects
The review committee will evaluate the pilot research projects recognizing that these are pilot projects and are not intended to be fully developed protocols. The committee will evaluate the potential of these projects to contribute to the development of research capability and skill among faculty and students.
(a) Value of the research question to the faculty member's development, the MIDARP program and the field.
(b) Appropriateness/adequacy of the literature review to demonstrate knowledge of the field and support the research question.
(c) Appropriateness of the proposed approach.
(d) Adequacy of the resources and support provided to the faculty investigator.
(e) Likelihood that the project director can administer the project with support of the program director and other institutional resources and support as needed.
5. Institutional Research Infrastructural Development Plan
Evaluate the description of the institutional needs, whether it will meet the drug abuse research infrastructure capacity goals proposed. Are the proposed resources and facilities, e.g., laboratory equipment, research space, etc. adequate to implement the proposed research development activities and to conduct the planned research. Are administrative support, collaborative arrangements, and data management and analysis support adequate? Evaluate the strategy for establishing and evaluating courses, curricula and seminars in areas relevant to research on drug abuse and addiction. Does the application propose and need enhancement of business and research administration capacity (e.g., IACUC, IRB, grants administration)?
6. MIDARP Program Director
Evaluate qualities, qualifications and potential of the Program Director in leading the MIDARP program to successfully achieving its goals. Criteria may include how well he/she can provide direction and leadership in the research proposed, support of the institution, and confidence of the faculty and students.
7. External Advisory Board
Assess the plans for the establishment of an external advisory panel to provide advice and consultation to the Program Director on the direction and progress of the MIDARP.
8. Letter of Institutional Commitment
Assess the Institutional commitment to the MIDARP by reviewing consideration of guarantees of protected time for faculty to engage in drug abuse research, and research mentoring; opportunities to recruit and retain quality under-represented minority faculty and students; and opportunities for career development for faculty engaged in drug abuse research.
9. Impact Assessment
Assess the likelihood that the proposed MIDARP will have a significant impact on the research capacity of the institution to engage in drug abuse research and in research career development of minority faculty and students, and fill a gap in drug abuse research at the applicant institution.
10. Or competing continuation applications, evaluate the extent to which the program has made progress in developing the research capacity, in faculty development and in student recruitment and development. In addition, evaluate what the primary research projects and pilot research projects have accomplished.. Examples of progress may include: participation of faculty and students in drug abuse research; increased support and conduct of drug abuse research; publication of manuscripts on drug abuse research; success obtaining other sources of funding; service in drug abuse related activities such as peer reviewers for research grants or contracts; indication of developing skills in students and faculty; new seminars or courses; recruitment of students and researchers; improvements in institutional processes and procedures related to sponsored research such as IRBs and other review requirements; students entering graduate programs with expressed interest in drug abuse; established collaborations with others around drug abuse research or activities; securing patents related to drug abuse research or treatment; etc. Applications submitted for their second and succeeding renewal continuation are expected to have made substantially more progress than those submitted for the first competing continuation.
2.A. Additional Review Criteria:
In addition to the above criteria, the following items will continue to be considered in the determination of scientific merit and the priority score:
Protection of Human Subjects from Research Risk: The involvement of human subjects and protections from research risk relating to their participation in the proposed research will be assessed (see the Research Plan, Section E on Human Subjects in the PHS Form 398).
Inclusion of Women, Minorities and Children in Research: The adequacy of plans to include subjects from both genders, all racial and ethnic groups (and subgroups), and children as appropriate for the scientific goals of the research will be assessed. Plans for the recruitment and retention of subjects will also be evaluated (see the Research Plan, Section E on Human Subjects in the PHS Form 398).
Care and Use of Vertebrate Animals in Research: If vertebrate animals are to be used in the project, the five items described under Section F of the PHS Form 398 research grant application instructions will be assessed.
2.B. Additional Review Considerations
Budget: The reasonableness of the proposed budget and the requested period of support in relation to the proposed research. The priority score should not be affected by the evaluation of the budget.
2.C. Sharing Research Data
Data Sharing Plan: The reasonableness of the data sharing plan or the rationale for not sharing research data will be assessed by the reviewers. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score. The presence of a data sharing plan will be part of the terms and conditions of the award. The funding organization will be responsible for monitoring the data sharing policy.
2.D. Sharing Research Resources
NIH policy requires that grant awardee recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (See the NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps/part_ii_5.htm#availofrr and http://www.ott.nih.gov/policy/rt_guide_final.html). Investigators responding to this funding opportunity should include a sharing research resources plan addressing how unique research resources will be shared or explain why sharing is not possible.
The adequacy of the resources sharing plan will be considered by Program staff of the funding organization when making recommendations about funding applications. Program staff may negotiate modifications of the data and resource sharing plans with the awardee before recommending funding of an application. The final version of the data and resource sharing plans negotiated by both will become a condition of the award of the grant. The effectiveness of the resource sharing will be evaluated as part of the administrative review of each non-competing Grant Progress Report (PHS 2590). See Section VI.3. Reporting.
3. Anticipated Announcement and Award Dates
Not applicable
1. Award Notices
After the peer review of the application is completed, the Principal Investigator will also receive a written critique called a Summary Statement.
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant. For details, applicants may refer to the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part4.htm).
A formal notification in the form of a Notice of Grant Award (NGA) will be provided to the applicant organization. The NGA signed by the grants management officer is the authorizing document.
If the grantee organization is set up to receive e-mailed awards from NIH, the award will be e-mailed to the authorized business official of the grantee institution. If the organization is not e-mailed enabled, one copy of the Notice of Award will be mailed to the authorized business official. The business official's office is responsible for sending a copy of the award to the Principal Investigator.
Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NGA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See Also Section IV.5. Funding Restrictions.
2. Administrative and National Policy Requirements
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the notice of grant award. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part4.htm) and Part II Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part9.htm).
Awardees will be required to submit the PHS Non-Competing Grant Progress Report, Form 2590 annually (http://grants.nih.gov/grants/funding/2590/2590.htm) and financial statements as required in the NIH Grants Policy Statement.
Section VII. Agency ContactsWe encourage your inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Inquiries may fall into three areas: scientific/research, peer review, and financial or grants management issues:
1. Scientific/Research Contacts:
Lula Beatty, Ph.D.
Special Populations Office
National Institute on Drug Abuse
6001 Executive Boulevard
Room 4216, MSC 9567
Bethesda, MD 20892-9567
Telephone: (301) 443-0441
FAX: (301) 480-8179
Email: [email protected]
A complete list of programmatic areas and staff may be found at http://www.drugabuse.gov/Funding/resfundslist.html.
2. Peer Review Contacts:
Teresa Levitin, Ph.D.
Director
Office of Extramural Affairs
National Institute on Drug Abuse/NIH/DHHS
6101 Executive Boulevard, Suite 220, MSC 8401
Bethesda, MD 20892-8401
Rockville, MD 20852 (for express/courier service)
Telephone: (301) 443-2755
FAX: (301) 443-0538
Email: [email protected]
3. Financial or Grants Management Contacts:
Gary Fleming, J.D.
Chief, Grants Management Branch/OPRM
National Institute on Drug Abuse/NIH/DHHS
6101 Executive Boulevard, Room 270
Bethesda, MD 20892
Telephone: (301) 443-6710
FAX: (301) 594-6849
Email: [email protected]
Required Federal Citations
Use of Animals in Research:
Recipients of PHS support for activities involving live, vertebrate animals must comply with PHS Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf) as mandated by the Health Research Extension Act of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm) as applicable.
Human Subjects Protection:
Federal regulations (45CFR46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Data and Safety Monitoring Plan:
Data and safety monitoring is required for all types of clinical trials, including physiologic toxicity and dose-finding studies (phase I); efficacy studies (Phase II); efficacy, effectiveness and comparative trials (Phase III). Monitoring should be commensurate with risk. The establishment of data and safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risks to the participants (NIH Policy for Data and Safety Monitoring, NIH Guide for Grants and Contracts, http://grants.nih.gov/grants/guide/notice-files/not98-084.html).
Sharing Research Data:
Investigators submitting an NIH application seeking $500,000 or more in direct costs in any single year are expected to include a plan for data sharing or state why this is not possible (http://grants.nih.gov/grants/policy/data_sharing).
Investigators should seek guidance from their institutions, on issues related to institutional policies and local IRB rules, as well as local, State and Federal laws and regulations, including the Privacy Rule. Reviewers will consider the data sharing plan but will not factor the plan into the determination of the scientific merit or the priority score.
Sharing of Model Organisms:
NIH is committed to support efforts that encourage sharing of important research resources including the sharing of model organisms for biomedical research (see http://grants.nih.gov/grants/policy/model_organism/index.htm). At the same time the NIH recognizes the rights of grantees and contractors to elect and retain title to subject inventions developed with Federal funding pursuant to the Bayh Dole Act (see the NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps_2003/index.htm). All investigators submitting an NIH application or contract proposal, beginning with the October 1, 2004 receipt date, are expected to include in the application/proposal a description of a specific plan for sharing and distributing unique model organism research resources generated using NIH funding or state why such sharing is restricted or not possible. This will permit other researchers to benefit from the resources developed with public funding. The inclusion of a model organism sharing plan is not subject to a cost threshold in any year and is expected to be included in all applications where the development of model organisms is anticipated.
Inclusion of Women And Minorities in Clinical Research:
It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing clinical research should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); a complete copy of the updated Guidelines is available at http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. The amended policy incorporates: the use of an NIH definition of clinical research; updated racial and ethnic categories in compliance with the new OMB standards; clarification of language governing NIH-defined Phase III clinical trials consistent with the new PHS Form 398; and updated roles and responsibilities of NIH staff and the extramural community. The policy continues to require for all NIH-defined Phase III clinical trials that: a) all applications or proposals and/or protocols must provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and b) investigators must report annual accrual and progress in conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group differences.
Inclusion of Children as Participants in Clinical Research:
The NIH maintains a policy that children (i.e., individuals under the age of 21) must be included in all clinical research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them.
All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines" on the inclusion of children as participants in research involving human subjects (http://grants.nih.gov/grants/funding/children/children.htm).
Required Education on the Protection of Human Subject Participants:
NIH policy requires education on the protection of human subject participants for all investigators submitting NIH applications for research involving human subjects and individuals designated as key personnel. The policy is available at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
Human Embryonic Stem Cells (hESC):
Criteria for federal funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp and at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov/). It is the responsibility of the applicant to provide in the project description and elsewhere in the application as appropriate, the official NIH identifier(s) for the hESC line(s)to be used in the proposed research. Applications that do not provide this information will be returned without review.
Public Access to Research Data through the Freedom of Information Act:
The Office of Management and Budget (OMB) Circular A-110 has been revised to provide public access to research data through the Freedom of Information Act (FOIA) under some circumstances. Data that are (1) first produced in a project that is supported in whole or in part with Federal funds and (2) cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., a regulation) may be accessed through FOIA. It is important for applicants to understand the basic scope of this amendment. NIH has provided guidance at http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm. Applicants may wish to place data collected under this PA in a public archive, which can provide protections for the data and manage the distribution for an indefinite period of time. If so, the application should include a description of the archiving plan in the study design and include information about this in the budget justification section of the application. In addition, applicants should think about how to structure informed consent statements and other human subjects procedures given the potential for wider use of data collected under this award.
Standards for Privacy of Individually Identifiable Health Information:
The Department of Health and Human Services (DHHS) issued final modification to the "Standards for Privacy of Individually Identifiable Health Information", the "Privacy Rule", on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the DHHS Office for Civil Rights (OCR).
Decisions about applicability and implementation of the Privacy Rule reside with the researcher and his/her institution. The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a complete Regulation Text and a set of decision tools on "Am I a covered entity?" Information on the impact of the HIPAA Privacy Rule on NIH processes involving the review, funding, and progress monitoring of grants, cooperative agreements, and research contracts can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
HIV/AIDS Counseling and Testing Policy for the National Institute on Drug Abuse: Researchers funded by NIDA who are conducting research in community outreach settings, clinical, hospital settings, or clinical laboratories and have ongoing contact with clients at risk for HIV infection, are strongly encouraged to provide HIV risk reduction education and counseling. HIV counseling should include offering HIV testing available on-site or by referral to other HIV testing service for persons at risk for HIV infection including injecting drug users, crack cocaine users, and sexually active drug users and their sexual partners. For more information see http://grants.nih.gov/grants/guide/notice-files/NOT-DA-01-001.html.
National Advisory Council on Drug Abuse Recommended Guidelines for the Administration of Drugs to Human Subjects: The National Advisory Council on Drug Abuse recognizes the importance of research involving the administration of drugs to human subjects and has developed guidelines relevant to such research. Potential applicants are encouraged to obtain and review these recommendations of Council before submitting an application that will administer compounds to human subjects. The guidelines are available on NIDA's Home Page at http://www.nida.nih.gov under the Funding, or may be obtained by calling (301) 443-2755.
URLs in NIH Grant Applications or Appendices:
All applications and proposals for NIH funding must be self-contained within specified page limitations. Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) should not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites. Furthermore, we caution reviewers that their anonymity may be compromised when they directly access an Internet site.
Healthy People 2010:
The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This PA is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
Authority and Regulations:
This program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The NIH Grants Policy Statement can be found at http://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Loan Repayment Programs:
NIH encourages applications for educational loan repayment from qualified health professionals who have made a commitment to pursue a research career involving clinical, pediatric, contraception, infertility, and health disparities related areas. The LRP is an important component of NIH's efforts to recruit and retain the next generation of researchers by providing the means for developing a research career unfettered by the burden of student loan debt. Note that an NIH grant is not required for eligibility and concurrent career award and LRP applications are encouraged. The periods of career award and LRP award may overlap providing the LRP recipient with the required commitment of time and effort, as LRP awardees must commit at least 50% of their time (at least 20 hours per week based on a 40 hour week) for two years to the research. For further information, please see: http://www.lrp.nih.gov/.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||